1. Home
  2. PZG vs PMN Comparison

PZG vs PMN Comparison

Compare PZG & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paramount Gold Nevada Corp.

PZG

Paramount Gold Nevada Corp.

SELL

Current Price

$0.94

Market Cap

84.0M

ML Signal

SELL

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$3.31

Market Cap

84.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZG
PMN
Founded
1992
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Metal Mining
Pharmaceuticals and Biotechnology
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.0M
84.1M
IPO Year
2015
2022

Fundamental Metrics

Financial Performance
Metric
PZG
PMN
Price
$0.94
$3.31
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $42.25
AVG Volume (30 Days)
265.9K
★ 377.2K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $330,259.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.88
$0.29
52 Week High
$2.70
$27.40

Technical Indicators

Market Signals
Indicator
PZG
PMN
Relative Strength Index (RSI) 41.67 30.28
Support Level $0.88 $2.78
Resistance Level $1.06 $15.05
Average True Range (ATR) 0.07 1.07
MACD 0.01 -0.06
Stochastic Oscillator 37.86 6.01

Price Performance

Historical Comparison
PZG
PMN

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold and Bald Peak Project.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: